Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793970

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793970

Hepatitis B and C Diagnostics

PUBLISHED:
PAGES: 275 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Hepatitis B and C Diagnostics Market to Reach US$9.6 Billion by 2030

The global market for Hepatitis B and C Diagnostics estimated at US$6.8 Billion in the year 2024, is expected to reach US$9.6 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Immunodiagnostics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Nucleic Acid Testing segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 9.1% CAGR

The Hepatitis B and C Diagnostics market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Hepatitis B and C Diagnostics Market - Key Trends & Drivers Summarized

Are Innovations in Diagnostic Technology Changing the Outlook for Hepatitis Detection?

The diagnostics landscape for Hepatitis B and C is undergoing a fundamental transformation driven by rapid advancements in medical technology, molecular biology, and point-of-care testing. These two forms of viral hepatitis, which collectively affect hundreds of millions worldwide, have long posed diagnostic challenges due to asymptomatic progression, limited screening in vulnerable populations, and the complexity of viral behavior in chronic cases. However, new technologies are now enabling earlier, faster, and more accurate detection of both HBV and HCV. Molecular assays, particularly nucleic acid amplification tests (NAATs), are emerging as the gold standard for confirming active viral infection and monitoring viral load. These tests offer high sensitivity and specificity, capable of identifying even low levels of viral RNA or DNA, which is critical for guiding treatment decisions. Simultaneously, advances in serological testing, including enzyme-linked immunosorbent assays (ELISA) and rapid diagnostic tests (RDTs), are making population-level screening more feasible, especially in low-resource settings. Innovations such as dried blood spot (DBS) testing, multiplex platforms, and automated immunoassay systems are increasing throughput while reducing turnaround times. The rise of digital diagnostics, including AI-assisted test interpretation and mobile-integrated diagnostic readers, is also extending access to underserved communities and improving data collection for public health interventions. Collectively, these innovations are pushing Hepatitis B and C diagnostics beyond hospital laboratories and into primary care, community clinics, and remote health centers-making early intervention, prevention of transmission, and disease management more achievable than ever before.

Is the Global Push for Elimination Driving Widespread Hepatitis Screening Initiatives?

Global public health initiatives, particularly those spearheaded by the World Health Organization (WHO), are playing a crucial role in elevating hepatitis diagnostics as a top healthcare priority. With WHO’s ambitious goal to eliminate viral hepatitis as a public health threat by 2030, countries are being urged to scale up screening, diagnosis, and linkage to care-especially among high-risk populations such as people who inject drugs, prisoners, sex workers, and individuals living with HIV. In response, governments and non-governmental organizations are ramping up community-based testing programs, mobile health units, and targeted outreach campaigns designed to increase diagnosis rates. As part of this effort, public health policies are increasingly mandating routine hepatitis testing in antenatal care, blood donations, and healthcare worker screenings, helping to normalize testing and reduce associated stigma. Additionally, funding from global health organizations such as the Global Fund, Gavi, and UNITAID is enabling developing countries to procure advanced testing technologies, improve laboratory capacity, and integrate hepatitis diagnostics into existing healthcare infrastructure. Regional partnerships in Asia-Pacific, Africa, and Latin America are also fostering knowledge sharing and standardized guidelines to ensure that testing strategies are both efficient and equitable. The adoption of simplified diagnostic algorithms-such as reflex testing and one-step confirmatory protocols-is further accelerating the path from screening to treatment initiation. Educational campaigns and awareness drives are playing a crucial role in encouraging individuals to get tested, particularly in communities where hepatitis remains poorly understood. This coordinated global movement is reshaping the diagnostics market, driving both volume and innovation as testing becomes a cornerstone of hepatitis elimination strategies worldwide.

How Are Decentralized Testing and Point-of-Care Solutions Expanding Access to Diagnostics?

The growing availability of decentralized and point-of-care (POC) diagnostic tools is dramatically expanding access to Hepatitis B and C testing, particularly in resource-limited and rural areas where laboratory infrastructure is minimal or nonexistent. These compact, easy-to-use diagnostic kits are revolutionizing outreach by enabling frontline health workers to conduct testing outside of traditional medical settings, such as in homes, schools, community centers, and refugee camps. POC tests based on lateral flow immunoassay technology allow for rapid detection of HBV surface antigen (HBsAg) or HCV antibodies with results in as little as 15 to 30 minutes. Many of these tests require only a finger-prick blood sample and do not rely on refrigeration, making them ideal for deployment in tropical or underserved regions. Moreover, advances in microfluidics, biosensors, and battery-powered analyzers are improving the accuracy and reliability of these decentralized tools, narrowing the performance gap between POC tests and centralized laboratory assays. Integration of POC testing with digital health platforms enables immediate recording and transmission of results, which facilitates real-time disease surveillance and follow-up care. In humanitarian settings and remote communities, task-shifting models-where trained non-physician health workers conduct screenings-are further increasing testing coverage and efficiency. The affordability of these solutions is also improving, with global procurement initiatives ensuring reduced-cost diagnostics for high-burden countries. This democratization of access is especially vital in achieving early diagnosis and intervention, reducing the time from detection to treatment, and supporting broader hepatitis elimination targets. As decentralized testing technologies continue to evolve, their role in overcoming logistical, financial, and geographic barriers to hepatitis care will only become more central.

What Key Market Forces Are Fueling Growth in the Hepatitis B and C Diagnostics Sector?

The growth in the Hepatitis B and C diagnostics market is driven by several factors rooted in rising disease prevalence, technological innovation, healthcare policy evolution, and shifting patterns in consumer behavior and provider priorities. The sheer scale of the global hepatitis burden-over 350 million individuals living with chronic HBV or HCV-provides a significant base for diagnostic demand, especially as treatment eligibility increasingly depends on precise viral quantification. Aging populations, rising rates of injection drug use, and increased migration from high-prevalence countries are further expanding the at-risk demographic. On the technological front, the emergence of next-generation molecular platforms, digital immunoassays, and AI-powered diagnostic analytics is accelerating test accuracy, speed, and affordability. Meanwhile, pharmaceutical advancements-particularly the availability of curative direct-acting antivirals (DAAs) for hepatitis C-are motivating more patients to seek diagnosis, creating a feedback loop of demand between treatment and diagnostics. Regulatory bodies across Europe, North America, and Asia are implementing screening mandates in blood banks, prenatal care, and hospital admissions, institutionalizing the role of hepatitis testing in public health policy. Concurrently, global investments in diagnostic infrastructure-bolstered by pandemic-era capacity building-are being repurposed to expand hepatitis testing. Consumer behavior is also changing; increased health literacy, the normalization of self-testing, and digital health tools are empowering individuals to proactively seek testing. Private diagnostic laboratories, telehealth services, and at-home testing kits are responding with customized services, further diversifying access. Combined, these forces are shaping a rapidly evolving market that is as much about innovation and access as it is about medical necessity-positioning hepatitis diagnostics as a critical frontier in the global fight against infectious diseases.

SCOPE OF STUDY:

The report analyzes the Hepatitis B and C Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Immunodiagnostics, Nucleic Acid Testing); Disease Type (Hepatitis B, Hepatitis C)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Affymetrix (Thermo Fisher)
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biomerieux SA
  • Cepheid (Danaher)
  • DiaSorin S.p.A.
  • Fujirebio (H.U. Group)
  • Grifols, S.A.
  • Hologic, Inc.
  • HORIBA, Ltd.
  • InTec Products, Inc.
  • Johnson & Johnson
  • MedMira Inc.
  • Ortho Clinical Diagnostics
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Trinity Biotech

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37076

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hepatitis B and C Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Chronic Hepatitis Infections Throws the Spotlight on Early and Accurate Diagnostics
    • Increased Government-Led Screening Initiatives Propel Growth in Population-Wide Testing Programs
    • Global Commitment to Viral Hepatitis Elimination Expands Addressable Market for Diagnostic Solutions
    • Advancements in Rapid Point-of-Care Testing Drive Adoption in Resource-Limited Settings
    • Integration of Molecular Diagnostics Strengthens Business Case for High-Sensitivity Viral Load Testing
    • Growing Public Health Focus on Blood Safety Generates Demand for Routine Hepatitis Screening
    • Widespread Use of Combination Panels and Multiplex Testing Spurs Efficiency in Diagnostic Workflows
    • Technological Innovation in PCR and Next-Generation Sequencing Accelerates Diagnostic Accuracy
    • Increased Access to Affordable Diagnostics Through Global Health Partnerships Sustains Market Growth
    • Expansion of At-Home and Self-Testing Solutions Drives Consumer-Centric Hepatitis Testing
    • Healthcare Digitization and Data Integration Throw the Spotlight on Real-Time Epidemiological Tracking
    • Rising Co-Infection Risks with HIV and TB Generate Demand for Integrated Diagnostic Platforms
    • Lack of Awareness and Underdiagnosis in Low-Income Regions Pose Persistent Challenges to Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatitis B and C Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatitis B and C Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunodiagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Nucleic Acid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Nucleic Acid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Nucleic Acid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hepatitis B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hepatitis C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • JAPAN
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • CHINA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • EUROPE
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Hepatitis B and C Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • FRANCE
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • GERMANY
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • INDIA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • AFRICA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!